Race Oncology Ltd (ASX:RAC) is heading to market with a capital raising, and the ASX has granted the company a trading halt to prepare.
The company recently executed a Letter of Intent with TargImmune Therapeutics AG to enter into a joint venture between the two companies.
The joint venture, to be called Race Immunotherapeutics, will focus on developing new and improved cancer therapies based on combining Bisantrene with TargImmune’s targeted cancer therapy technology.
The halt will remain in place until the opening of trade on Monday 17th July 2017, or earlier if an announcement is made to the market.